HLB Therapeutics Shares Plummet After Phase 3 Trial Fails to Meet Primary Endpoint

HLB Therapeutics' candidate treatment for neurotrophic keratitis, RGN-259, saw its stock price plummet after failing to meet the primary endpoint in a Phase 3 clinical trial in the United States.


As of 9:32 a.m. on November 16, HLB Therapeutics was trading at 1,635 won, down 700 won (29.98%) from the previous trading day, according to the Korea Exchange.


The company announced that its U.S. subsidiary, Regentree, did not achieve statistical significance for the primary endpoint in the Phase 3 trial of RGN-259. The primary endpoint, which compared the cure rates four weeks after administration, showed no statistically significant difference between the RGN-259 treatment group and the placebo group.


RGN-259 is a new drug candidate in the form of eye drops, primarily composed of the regenerative protein thymosin beta-4. It is being developed as a treatment for neurotrophic keratitis, a condition where damage to the corneal nerves reduces sensation and the natural healing ability of the cornea.


The company plans to conduct further analysis to comprehensively review the overall clinical results, including the complete results of the primary endpoint, secondary endpoints, and treatment responses by subgroup.





* This article has been translated by AI.